AdvaMed Lobbies Chinese Government Ahead Of Expected Price Cuts
This article was originally published in PharmAsia News
Executive Summary
CEO Stephen Ubl said AdvaMed is looking to "explore alternatives to price controls" in recent talks with officials.
You may also be interested in...
Chinese Government Takes First Steps To De-link Indigenous Innovation And Procurement, But Industry Groups Wary
SHANGHAI - Months after pledging a policy change, China is finally taking steps to break ties between indigenous innovation and government procurement policies. The changes in policy, according to a report released by the U.S.-China Business Council, address growing concern among multinationals that procurement policies - an estimated $1 trillion market - are increasingly designed to shut them out
China's Device Classification System And Country Of Origin Requirements Weigh On Foreign Companies
BEIJING - Foreign medical device manufacturers frustrated with China's medical device classification system and country of origin requirements are starting to take an "if you can't beat them, joint them" approach and are shifting more manufacturing to China, according to panelists at a recent regulatory conference in Beijing
FCPA In The China Framework Warrants Special Attention
The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?